Art. -Nr.: HY-N0063

Punicalagin

17 Cited Publications

Kundenbewertung

Based on 17 publication(s) in Google Scholar

Punicalagin is a polyphenol ingredient isolated from Pomegranate (Punica granatum L.) or the leaves of Terminalia catappa L.. Punicalagin is a reversible and non-competitive 3CL^pro inhibitor and inhibits SARS-CoV-2 replication in vitro. Punicalagin is an anti-hepatitis B virus (HBV) agent and has antioxidant, anti-inflammatory, and anticancer effects. Punicalagin has the potential for the research of COVID-19.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.89%
CAS. Nr.: 65995-63-3
Formel: C₄₈H₂₈O₃₀
Molecular Weight:1084.72

Speicherung:

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Punicalagin Chemical Structure

CAS. Nr.: 65995-63-3

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- In Vitro
- In Vivo
- Clinical Trial
Chemical Information
Publications (17)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

In Vitro

Punicalagin (100 mg/ml) induces apoptosis in HT-29, HCT116 colon cells^[1].
Punicalagin slightly inhibits the PL^pro activity with an IC₅₀ of over 50 μM. Punicalagin inhibits the plaque formation of SARS-CoV-2 in a dose-dependent manner, with EC₅₀ values of 7.20 μM^[4].
Punicalagin binds at an allosteric site in the dimer interface. Punicalagin inhibit SARS-CoV-2 replication by a mechanism other than preventing S-mediated viral entry^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Punicalagin (10 mg/kg) inhibits the edema rate of 58.15% in rats^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS. Nr. 65995-63-3
Appearance Solid
Molecular Weight 1084.72
Formel C₄₈H₂₈O₃₀
Color Light yellow to yellow
SMILES

O=C(C1=C(C2=C(O)C(O)=C(O)C=C2C(O[C@@H]3[C@@H](CO4)OC(O)[C@H](OC5=O)[C@H]3OC(C6=CC(O)=C(O)C(O)=C6C7=C5C=C(O)C(O)=C7O)=O)=O)C(O)=C8O)OC(C(C1=C8O9)=C%10C9=O)=C(O)C(O)=C%10C%11=C(C4=O)C=C(O)C(O)=C%11O
Structure Classification
- Phenols
- Polyphenols
Initial Source
Versand

Room temperature in continental US; may vary elsewhere.
Speicherung

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Publications (17)

All In Vivo Efficacy StudyRT-PCRHistological Imaging/StainingWBIn Vivo ImagingIF

Sort by:

Journal Impact Factor

Acta Pharmacol Sin

Salvianolic acid A from Salvia miltiorrhiza identified as a cap-dependent endonuclease inhibitor for pathogenic arenaviruses. [Abstract]

2025 Sep 3. PMID: 40903541

Punicalagin purchased from MedChemExpress. Usage Cited in: Acta Pharmacol Sin. 2025 Sep 3. [Abstract]

Body weight changes in Female BALB/c mice aged 6–8 weeks after treatment with 20 mg/kg of Salvianolic acid A (SAA), Chebulinic Acid, Tannic acid, or Punicalagin via i.g. upon challenge once daily for 3 days. 300 mg/kg T-705 administered via i.g. was used as a positive control.

Punicalagin purchased from MedChemExpress. Usage Cited in: Acta Pharmacol Sin. 2025 Sep 3. [Abstract]

T-705 and SAA significantly reduced viral copies in the liver in Female BALB/c mice aged 6–8 weeks after treatment with 20 mg/kg of Salvianolic acid A (SAA), Chebulinic Acid, Tannic acid, or Punicalagin via i.g. upon challenge once daily for 3 days. 300 mg/kg T-705 administered via i.g. was used as a positive control.
Phytomedicine

Punicalagin inhibits excessive autophagy and improves cerebral function in neonatal rats with hypoxia-ischemia brain injury by regulating AKT-FOXO4. [Abstract]

2025 Jan 1:136:156330. PMID: 39756314

Punicalagin purchased from MedChemExpress. Usage Cited in: Phytomedicine. 2025 Jan 1:136:156330. [Abstract]

Punicalagin (PUN)-treated HIE group was administered various doses of PUN (10 and 20 mg/kg) 24 h before hypoxia by intraperitoneal (i.p.) injection at 24 h intervals in Sprague-Dawley (SD) rats. The mRNA expression of the inflammatory factors Ccl6, Lgals3, C1qa, TYROBP, and CD74 in the brain tissues 48 h postoperatively, normalized to GAPDH for each sample. PUN can effectively reduce the inflammatory response in brain tissue after HIE, while the AKT signaling pathway inhibitor 3-MA reversed this therapeutic effect.

Punicalagin purchased from MedChemExpress. Usage Cited in: Phytomedicine. 2025 Jan 1:136:156330. [Abstract]

Punicalagin (PUN)-treated HIE group was administered various doses of PUN (10 and 20 mg/kg) 24 h before hypoxia by intraperitoneal (i.p.) injection at 24 h intervals in Sprague-Dawley (SD) rats. Representative images of HE staining in the cortex post-operatively.

Punicalagin purchased from MedChemExpress. Usage Cited in: Phytomedicine. 2025 Jan 1:136:156330. [Abstract]

Punicalagin (PUN)-treated HIE group was administered various doses of PUN (10 and 20 mg/kg) 24 h before hypoxia by intraperitoneal (i.p.) injection at 24 h intervals in Sprague-Dawley (SD) rats. Representative Western blot images and quantification of Bcl-2 and Bax expression three days post-operation in the cortex.

Punicalagin purchased from MedChemExpress. Usage Cited in: Phytomedicine. 2025 Jan 1:136:156330. [Abstract]

Punicalagin (PUN)-treated HIE group was administered various doses of PUN (10 and 20 mg/kg) 24 h before hypoxia by intraperitoneal (i.p.) injection at 24 h intervals in Sprague-Dawley (SD) rats. Representative TUNEL-stained (green) and DAPI-stained (blue) brain sections of the cortex three days post-operatively. Quantitative analysis of the percentage of TUNEL-positive cells in the cortex.

Punicalagin purchased from MedChemExpress. Usage Cited in: Phytomedicine. 2025 Jan 1:136:156330. [Abstract]

Punicalagin (PUN)-treated HIE group was administered various doses of PUN (10 and 20 mg/kg) 24 h before hypoxia by intraperitoneal (i.p.) injection at 24 h intervals in Sprague-Dawley (SD) rats. Representative images of immunohistochemical staining of p-AKT and immunofluorescence staining for p62 (red) and LC3 (green) in the cortex of each group at 72 h post-HI.
Antioxid Redox Signal

Punicalagin Protects Against Diabetic Cardiomyopathy by Promoting Opa1-Mediated Mitochondrial Fusion via Regulating PTP1B-Stat3 Pathway. [Abstract]

2021 Sep;35(8):618-641. PMID: 33906428
Chem Biol Interact

Punicalagin alleviates enterotoxigenic Escherichia coli-induced intestinal mucosal injury via Krüppel-like factor 4. [Abstract]

2026 Jul 25:435:112182. PMID: 42219142
Biol Direct

Integrative transcriptomic profiling reveals NK cell exhaustion-associated prognostic genes and identifies CSF1 as a key immunoregulatory target in hepatocellular carcinoma. [Abstract]

2026 Apr 28;21(1):102. PMID: 42050573
ACS Omega

Identification of New Modulators and Inhibitors of Palmitoyl-Protein Thioesterase 1 for CLN1 Batten Disease and Cancer. [Abstract]

2024 Feb 28;9(10):11870-11882. PMID: 38496939
J Chromatogr A

Screening and identification of acetylcholinesterase inhibitors from Terminalia chebula fruits by immobilized enzyme on cellulose filter paper coupled with ultra-performance liquid chromatography-quadrupole time-of-flight mass spectrometry and molecular docking. [Abstract]

2022 Jan 25:1663:462784. PMID: 34974370
Antiviral Res

Discovery of chebulagic acid and punicalagin as novel allosteric inhibitors of SARS-CoV-2 3CLpro. [Abstract]

2021 Jun:190:105075. PMID: 33872675
Mol Divers

Targeting histidine biosynthesis in Acinetobacter baumannii: structure-based discovery of natural inhibitors of ATP-phosphoribosyltransferase. [Abstract]

2025 Nov 13. PMID: 41231374
Virol J

Mechanism research of Punicalagin in treating representative strains of enterovirus A and B types based on systems pharmacology and experimental validation. [Abstract]

2025 Jul 9;22(1):229. PMID: 40634970
Exp Cell Res

Punicalagin attenuates TNF-α-induced oxidative damage and promotes osteogenic differentiation of bone mesenchymal stem cells by activating the Nrf2/HO-1 pathway. [Abstract]

2023 Sep 1;430(1):113717. PMID: 37429372
BMC Complement Med Ther

Punicalagin, a pomegranate polyphenol sensitizes the activity of antibiotics against three MDR pathogens of the Enterobacteriaceae. [Abstract]

2024 Feb 16;24(1):93. PMID: 38365729
Vet Microbiol

The Chinese medicine monomer Schisandrin C inhibits PRRSV infection by regulating the OGT-PI3K/AKT/mTOR signaling pathway. [Abstract]

2026 May:316:110992. PMID: 41865607
BMC Vet Res

The impact of enriching heat-stressed rabbit diets with flaxseed oil with/ without allicin, lycopene, or Punicalagin on antioxidative status, physiological response and meat omega-3. [Abstract]

2025 Mar 20;21(1):187. PMID: 40114098
Vet Sci

Punicalagin Inhibits African Swine Fever Virus Replication by Targeting Early Viral Stages and Modulating Inflammatory Pathways. [Abstract]

2024 Sep 19;11(9):440. PMID: 39330819
SSRN

2025 May 09.
bioRxiv

2025 February 27.

Lösungsmittel & Löslichkeit

In Vitro:

H₂O : 100 mg/mL (92.19 mM; Need ultrasonic)

DMSO : 50 mg/mL (46.09 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

0.9219 mL

4.6095 mL

9.2190 mL

5 mM

0.1844 mL

0.9219 mL

1.8438 mL

10 mM

0.0922 mL

0.4609 mL

0.9219 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.17 mg/mL (2.00 mM); Clear solution

This protocol yields a clear solution of ≥ 2.17 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (21.7 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.17 mg/mL (2.00 mM); Clear solution

This protocol yields a clear solution of ≥ 2.17 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (21.7 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Working solution concentration: 0.22 mg/mL

This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact

MedChemExpress (MCE) .

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (286 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Seeram NP, et al. In vitro antiproliferative, apoptotic and antioxidant activities of punicalagin, ellagicacid and a total pomegranate tannin extract are enhanced in combination with otherpolyphenols as found in pomegranate juice. J Nutr Biochem. 2005 Jun;16(6):360-7. [Content Brief]

[2]. Lin CC, et al. Effects of punicalagin and punicalin on carrageenan-induced inflammation in rats. Am J Chin Med. 1999;27(3-4):371-6. [Content Brief]

[3]. Liu C, et al. Identification of hydrolyzable tannins (punicalagin, punicalin and geraniin) as novel inhibitors of hepatitis B virus covalently closed circular DNA. Antiviral Res. 2016 Oct;134:97-107. [Content Brief]

[4]. RuikunDu, et al. Discovery of Chebulagic Acid and Punicalagin as Novel Allosteric Inhibitors of SARS-CoV-2 3CLpro. Antivir Res. 2021, 105075. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO / H₂O	1 mM	0.9219 mL	4.6095 mL	9.2190 mL	23.0474 mL
	5 mM	0.1844 mL	0.9219 mL	1.8438 mL	4.6095 mL
	10 mM	0.0922 mL	0.4609 mL	0.9219 mL	2.3047 mL
	15 mM	0.0615 mL	0.3073 mL	0.6146 mL	1.5365 mL
	20 mM	0.0461 mL	0.2305 mL	0.4609 mL	1.1524 mL
	25 mM	0.0369 mL	0.1844 mL	0.3688 mL	0.9219 mL
	30 mM	0.0307 mL	0.1536 mL	0.3073 mL	0.7682 mL
	40 mM	0.0230 mL	0.1152 mL	0.2305 mL	0.5762 mL
H₂O	50 mM	0.0184 mL	0.0922 mL	0.1844 mL	0.4609 mL
	60 mM	0.0154 mL	0.0768 mL	0.1536 mL	0.3841 mL
	80 mM	0.0115 mL	0.0576 mL	0.1152 mL	0.2881 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Keywords

Punicalagin

17 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Punicalagin

Anti-Infection Compound Library

Natural Product Library

Anti-Cancer Compound Library

Clinical Compound Library

Antiviral Compound Library

Drug Repurposing Compound Library

Antioxidant Compound Library

Medicine Food Homology Compound Library

Phenols Library

Traditional Chinese Medicine Active Compound Library

Food-Sourced Compound Library

Anti-Cancer Natural Product Library

Antiviral Traditional Chinese Medicine Active Compound Library

Plant-Sourced Natural Product Library

Human Metabolite Library

Multi-Target Compound Library

Radioprotector Library

Bioactive Compound Library Max

Natural Product Library Plus

Drug Repurposing Compound Library Plus

Clinical Compound Library Plus

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Anti-Fibrosis Compound Library

Miao Ethnicity Medicine Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Ancient Chinese Classical Formulas Traditional Chinese Medicine Active Compound Library

Mass Spectrometry Human Metabolite Library

Diarrhea-Related Traditional Chinese Medicine Active Compound Library

Mongolian Medicine Compound Library

Natural Product Diversity Scaffold Library

Mass Spectrometry Natural Product Library

Publications Citing Use of MedChemExpress (MCE) Punicalagin

Biologische Aktivität

Chemical Information

Publications (17)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Punicalagin Related Classifications

HY-N0063 Related Classifications